Eiger Biopharmaceuticals Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Eiger Biopharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2015).
SEC Form D · Nov 2015
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2015
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Eiger Biopharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David Cory | Executive officer | Nov 2015 |
| Glen Sato | Executive officer | Aug 2012 |
| Keith Vendola | Executive officer | Sep 2010 |
| Wenjin Yang | Executive officer | Sep 2010 |
| David Cory | Director | Nov 2015 |
| Ed Engleman | Director | Nov 2015 |
| Jeffrey Glenn | Director | Nov 2015 |
| Nina Kjellson | Director | Nov 2015 |
| Thomas Dietz | Director | Nov 2015 |
| Paul Truex | Director | Aug 2012 |